title: Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation.
abstract: We recently reported that adolescents and young adults (AYAs) with B-cell ALL receiving allogeneic hematopoietic cell transplantation (allo-HCT) have inferior survival compared with children, primarily because of greater TRM. We therefore hypothesized that in the setting of allo-HCT for AML, similar inferior outcomes would be observed in AYA patients as compared with children. We reviewed outcomes of 168 consecutive patients (ages 0-30 years) with AML undergoing allo-HCT at our institution. Of these, 60% (n=101) were <15 years of age and 40% (n=67) were AYAs (15-30 years of age). We identified no significant differences in 5-year overall survival (48% vs 50%, P=0.89), disease-free (47% vs 47%, P=0.89), relapse (24% vs 33%, P=0.30) or TRM (27% vs 16%, P=0.10) between the two groups. However, AYA patients had a greater incidence of grade II-IV acute (48% vs 31%, P=0.01) and chronic GVHD (22% vs 7%, P<0.01). Based on this analysis we identified no differences in survival, relapse or TRM between AYAs and children with AML receiving allo-HCT.
authors.affiliation: Division of Pediatric Hematology-Oncology-BMT, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Burke
authors.affiliation: Department of Pediatrics, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN, USA.
authors.forename: N
authors.initials: N
authors.lastname: Gossai
authors.affiliation: Biostatistic Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
authors.forename: Q
authors.initials: Q
authors.lastname: Cao
authors.affiliation: Division of Pediatric Blood and Marrow Transplantation, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Macmillan
authors.affiliation: Division of Blood and Marrow transplantation, University of Minnesota, Minneapolis, MN, USA.
authors.forename: E
authors.initials: E
authors.lastname: Warlick
authors.affiliation: Division of Pediatric Blood and Marrow Transplantation, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Verneris
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014182:Transplantation, Autologous / Q000009:adverse effects*; D016896:Treatment Outcome; D055815:Young Adult